Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.

This study aimed to retrospectively evaluate the circulating free DNA (cfDNA) level in patients with locally advanced breast cancer (LABC) having different neoadjuvant chemotherapy (NCT) responses and to investigate whether dynamic changes in cfDNA level could predict the effectiveness of NCT in patients with LABC. Data on 61 patients with LABC were included. NCT responses were evaluated using the response evaluation criteria. Blood samples were collected for cfDNA detection before treatment and after the first and eighth courses of chemotherapy. The Alu 111-bp and 260-bp fragment levels were evaluated by polymerase chain reaction, and the predictive value of the cfDNA level in the NCT response was determined. In vitro, the MCF-7 and MCF-7/ADR cell lines were applied to simulate the phenomenon of drug resistance and explain the underlying mechanism. The Alu 111-bp level increased after the first NCT course (P = .014) and then remained high after NCT in the high-R group (P = .047), but it remained steady in the low-R group during NCT. A similar tendency in the Alu 260-bp level was revealed in different groups. The increment increment Ct value of Alu 260-bp had good diagnostic efficiency in assessing predictive ability. The area under the curve for the increment increment Ct1 and increment increment Ct2 of Alu 260-bp was 0.697 and 0.647, respectively. The cfDNA level was closely related to epirubicin-induced apoptosis and changes in the Ki-67 index in vitro. The elevation of cfDNA after one chemotherapy cycle was mediated by the apoptosis of tumor cells and related to the improved chemotherapy response.